TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants With HER2 Status in Breast Cancer Specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Different Phenotypes of Breast Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With ER Status (Positive or Negative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in percent recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Vertical height deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotational axis misalignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of major adverse cardiac and cerebrovascular event (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Cervical volume and funneling changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysfunctional trauma-related appraisals
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Four-hour Dialysate to Plasma ratio of creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in peritoneal ultrafiltration capacity over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum 25OH-vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Local Leukotriene Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Headache pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Numeric Rating Scale (pain intensity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aphakic refractive measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawal Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Visual and refractive outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quotient of gross motor development change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve plasma concentration versus time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to PrEP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Return of patients for annual scans
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of pregnancies after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of live births after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Participants With Systolic BP Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Completed at Least 1 Video Visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fraud Detection Post Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported Difficulty With Instrumental Activities of Daily Living (IADLs) Post Training
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Driving Simulator Hazard Perception Post Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Life threatening bleeding complication
Endpoint domain: Adverse events/effects
Primary endpoint: Major or minor bleeding complication without life threatening condition
Endpoint domain: Adverse events/effects
Primary endpoint: changes in scores on Freezing of Gait Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall diagnostic yield of EUS-TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score on the YMRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days abstinent from substances of abuse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: stone free state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Barriers to Insulin Treatment (BIT) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Standard deviation of error between operator-measured flow measurements and actual flow measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in plasma HIV-1 RNA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of HIV-1 RNA levels below the limit of quantitation (BLQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of difficult laparoscopic cholecystectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Nasal tip resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness to quit
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in number of inflammatory acne lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Local Impedance Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PVI Gaps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Maximum Pain Level Decreased by ≥ 2 Points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase of the ejection fraction of the left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Numeric Pain Rating Scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response (opioid abstinence without severe withdrawal symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index (BMI) z-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of post herpetic neuralgia (PHN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Indices of Bone Turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in Bayleys Scale for Infant Development score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Detection rate of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically significant laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in the appearance of fungal nail
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: refractive outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with level of anti-PRP antibodies >1.0 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with level of anti-HBsAg antibodies ≥10 mIU/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with a ≥4-fold rise in levels of antibodies to pertussis antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of participants with level of anti-diphtheria antibodies ≥0.01 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in total atheroma volume (TAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of physical restraint episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Urinary Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients who remain alive in the first complete remission (CR) 1 year from achievement of CR
Endpoint domain: Mortality/survival
Primary endpoint: Self-Esteem
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adolescent Psychotic-Like Symptom Screener (APSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of individuals with s-MBL < 100 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of individuals with MBL genotypes LXPA/O or O/O
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Nutritional Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Body Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events Associated with Potential Liver Damage
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of Ambulation (LOA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Rise From the Floor (Supine to Stand)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Walk/Run 10 Meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of Upper Limb Module for DMD 2.0 (PUL 2.0) Entry Item A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary Function, as Measured by Forced Vital Capacity (FVC) (% Predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: General medical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of second cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Albendazole concentration in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with endoscopic recurrence at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: smoke and nicotine exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportions of participants with severe adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of CMV infection
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle Excitability Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Penn Spasm Frequency Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Three-dimensional kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Circulating Tumor Cells (CTCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Disseminated Tumor Cells in Bone Marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: composite of major cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Teeth with no clinical signs of pulp degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of stage N2 sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Mean Sitting Diastolic Blood Pressure (siSBP) reaching treatment goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low Density Lipoprotein-Cholesterol (LDL-C) level reaching treatment goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of gastrointestinal AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Taurine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival outcome
Endpoint domain: Mortality/survival
Primary endpoint: Inhalation profile parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharyngometry measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant-load exercise tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening Uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence and Severity of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: T and B cell subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ cell differentiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion Reporting HIV Testing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in HADS-Anxiety score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delayed onset muscle soreness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficacy of elbasvir/grazoprevir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Clinically Significant Effects (Adverse Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Money spent gambling
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of gambling sessions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disease-free three-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Functional Assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prediction of future development of clinical disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum Inflammatory Cell Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Abnormal hormonal response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incidence of Legionella pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: Exotropia Control Score at Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Reporting Any Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: length of sickness absence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in plasma concentration of Rosiglitazone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinical improvement using modified Davey's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin thickness planes using high frequency skin ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in cartilage thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gradient of minute ventilation vs end tidal CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Psychotic Symptom Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-traumatic Stress Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of oxytocin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adherence to the MAD
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Relative Abundance of Staphylococcus Aureus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects achieving HbA1c < 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Markedly Abnormal Clinical Laboratory Parameter Values During Treatment and Follow-up Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Post Natal Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Event-free survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Leg pain severity (0-100 VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with surgery procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in leg muscle electromyographic activation onset latency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in centre of pressure movement pathway in standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food intake (kcalories)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median length of hospital stays
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients with feasible PRS injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of chronic phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of first intravascular access attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Resolution of ear discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ear outcomes
Primary endpoint: cycle pregnancy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: PSA Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant adoption of TMI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Retention in the TMI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-reported abstinence at week 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With PSA at or Below 0.2 ng/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV RNA Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Pattern electroretinogram (PERG) examination results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Serum sodium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of onychodystrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Bacterial population diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline of Effects of Stress and Coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post-operative urinary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline Burnout at six months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline Morning Plasma Cortisol at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline Thyroid Related Hormones at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Dressing Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Carbon Dioxide Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Folic acid deficiency by religious origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vitamin B12 deficiency by age group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes